Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 530

1.

Development of biomarkers to chart all Alzheimer's disease stages: the royal road to cutting the therapeutic Gordian Knot.

Hampel H, Lista S, Khachaturian ZS.

Alzheimers Dement. 2012 Jul;8(4):312-36. doi: 10.1016/j.jalz.2012.05.2116. Review.

PMID:
22748938
2.

The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.

Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, Herholz K, Jack CR Jr, Sperling R, Cummings J, Blennow K, O'Bryant S, Frisoni GB, Khachaturian A, Kivipelto M, Klunk W, Broich K, Andrieu S, de Schotten MT, Mangin JF, Lammertsma AA, Johnson K, Teipel S, Drzezga A, Bokde A, Colliot O, Bakardjian H, Zetterberg H, Dubois B, Vellas B, Schneider LS, Hampel H.

J Prev Alzheimers Dis. 2014 Dec;1(3):181-202.

3.

PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease.

Hampel H, O'Bryant SE, Castrillo JI, Ritchie C, Rojkova K, Broich K, Benda N, Nisticò R, Frank RA, Dubois B, Escott-Price V, Lista S.

J Prev Alzheimers Dis. 2016 Dec;3(4):243-259. doi: 10.14283/jpad.2016.112. Epub 2016 Sep 6.

4.

Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans.

Saykin AJ, Shen L, Yao X, Kim S, Nho K, Risacher SL, Ramanan VK, Foroud TM, Faber KM, Sarwar N, Munsie LM, Hu X, Soares HD, Potkin SG, Thompson PM, Kauwe JS, Kaddurah-Daouk R, Green RC, Toga AW, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Jul;11(7):792-814. doi: 10.1016/j.jalz.2015.05.009. Review.

5.

[The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].

Croisile B, Auriacombe S, Etcharry-Bouyx F, Vercelletto M; National Institute on Aging (u.s.); Alzheimer Association.

Rev Neurol (Paris). 2012 Jun;168(6-7):471-82. doi: 10.1016/j.neurol.2011.11.007. Epub 2012 May 12. Review. French.

PMID:
22579080
6.

The future of Alzheimer's disease: the next 10 years.

Hampel H, Prvulovic D, Teipel S, Jessen F, Luckhaus C, Frölich L, Riepe MW, Dodel R, Leyhe T, Bertram L, Hoffmann W, Faltraco F; German Task Force on Alzheimer's Disease (GTF-AD).

Prog Neurobiol. 2011 Dec;95(4):718-28. doi: 10.1016/j.pneurobio.2011.11.008. Epub 2011 Nov 22. Review.

PMID:
22137045
7.

Imaging epigenetics in Alzheimer's disease.

Lista S, Garaci FG, Toschi N, Hampel H.

Curr Pharm Des. 2013;19(36):6393-415. Review.

PMID:
23432717
8.

Design of comprehensive Alzheimer's disease centers to address unmet national needs.

Trojanowski JQ, Arnold SE, Karlawish JH, Brunden K, Cary M, Davatzikos C, Detre J, Gaulton G, Grossman M, Hurtig H, Jedrziewski K, McCluskey L, Naylor M, Polsky D, Schellenberg GD, Siderowf A, Shaw LM, Van Deerlin V, Wang LS, Werner R, Xie SX, Lee VM.

Alzheimers Dement. 2010 Mar;6(2):150-5. doi: 10.1016/j.jalz.2009.11.004.

9.

Biomarkers in Sporadic and Familial Alzheimer's Disease.

Lista S, O'Bryant SE, Blennow K, Dubois B, Hugon J, Zetterberg H, Hampel H.

J Alzheimers Dis. 2015;47(2):291-317. doi: 10.3233/JAD-143006. Review.

PMID:
26401553
10.

Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement.

Hampel H, Lista S.

J Nutr Health Aging. 2013 Jan;17(1):54-63. doi: 10.1007/s12603-013-0003-1.

PMID:
23299381
11.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
12.

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020.

Hampel H, Lista S, Teipel SJ, Garaci F, Nisticò R, Blennow K, Zetterberg H, Bertram L, Duyckaerts C, Bakardjian H, Drzezga A, Colliot O, Epelbaum S, Broich K, Lehéricy S, Brice A, Khachaturian ZS, Aisen PS, Dubois B.

Biochem Pharmacol. 2014 Apr 15;88(4):426-49. doi: 10.1016/j.bcp.2013.11.009. Epub 2013 Nov 22. Review.

PMID:
24275164
13.

Biomarkers for preclinical Alzheimer's disease.

Tan CC, Yu JT, Tan L.

J Alzheimers Dis. 2014;42(4):1051-69. doi: 10.3233/JAD-140843. Review.

PMID:
25024325
14.

Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies.

Lista S, Dubois B, Hampel H.

J Nutr Health Aging. 2015 Feb;19(2):154-63. doi: 10.1007/s12603-014-0515-3. Review.

PMID:
25651440
15.
16.

Harmonized diagnostic criteria for Alzheimer's disease: recommendations.

Morris JC, Blennow K, Froelich L, Nordberg A, Soininen H, Waldemar G, Wahlund LO, Dubois B.

J Intern Med. 2014 Mar;275(3):204-13. doi: 10.1111/joim.12199.

17.

Evolving Relevance of Neuroproteomics in Alzheimer's Disease.

Lista S, Zetterberg H, O'Bryant SE, Blennow K, Hampel H.

Methods Mol Biol. 2017;1598:101-115. doi: 10.1007/978-1-4939-6952-4_5. Review.

PMID:
28508359
18.

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R; Contributors.

Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018. Review.

19.

Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer's disease.

Teipel SJ, Sabri O, Grothe M, Barthel H, Prvulovic D, Buerger K, Bokde AL, Ewers M, Hoffmann W, Hampel H.

J Alzheimers Dis. 2013;33 Suppl 1:S329-47. doi: 10.3233/JAD-2012-129030. Review.

PMID:
22735677
20.

Current insights into the pathophysiology of Alzheimer's disease: selecting targets for early therapeutic intervention.

Hampel H.

Int Psychogeriatr. 2012 Aug;24 Suppl 1:S10-7. doi: 10.1017/S1041610212000579. Review.

PMID:
22784422

Supplemental Content

Support Center